A Diagnostic Accuracy Study of Xpert®MTB/RIF in HIV-Positive Patients with High Clinical Suspicion of Pulmonary Tuberculosis in Lima, Peru

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Carriquiry, Gabriela ^a,b   Otero, Larissa ^b   González Lagos, Elsa ^a,b   Zamudio, Carlos ^b   Sánchez, Eduardo ^c   Nabeta, Pamela ^d   Campos, Miguel ^a,b   Echevarría, Juan ^a,b,e   Seas, Carlos ^a,b,e   Gotuzzo, Eduardo ^a,b,e  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^c Hospital Nacional Hipólito Unanue   (Kenya)

^d FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^e Departamento de Enfermedades Infecciosas y Tropicales   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LOWENSTEIN JENSEN CULTURE; LOWENSTEIN JENSEN PROPORTION METHOD; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MOLECULAR DIAGNOSIS; MTB RIF ASSAY; MYCOBACTERIA GROWTH INDICATOR TUBE; OUTCOME ASSESSMENT; PERU; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SPUTUM SMEAR;

ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; PERU; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS, PULMONARY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84866111335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044626     Document Type: Article

References (30)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Int Med 163(9): 1009-1021.
2. Sterling TR, Pham PA, Chaisson RE, (2010) HIV infection-related tuberculosis: clinical manifestations and treatment. clin infect dis 50: S223-S230.
3. Getahun H, Gunneberg C, Granich R, Nunn P, (2010) HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 50: S201-S207.
4. Lawn SD, Zumla AI, (2011) Tuberculosis. Lancet 378(9785): 57-72.
5. Mathew P, Kuo YH, Vazirani B, Eng RH, Weinstein MP, (2002) Are three sputum acid-fast bacillus smears necessary for discontinuing tuberculosis isolation? J Clin Microbiol 40(9): 3482-3484.
6. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375(9728): 1830-1843.
7. Toman K (2004) What are the main causes of false-positive and false-negative sputum smears? In: Frieden T, editor. Toman. Second edition. Geneva: World Health Organization WHO/HTM/TB/2004.334; 23-27.
8. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W, (2010) Xpert® MTB/RIF for point-of care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev. Mol. Diagn 10(7): 937-946.
9. Lawn SD, Nicol MP, (2011) Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 6(9): 1067-1082.
10. Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal Monte P, et al. (2012) Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J. Epub 40(2): 442-447.
11. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363(11): 1005-1015.
12. Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, et al. (2011) Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid XpertMTB/RIF assay-A clinical validation study. Plos One 6(6): e20458.
13. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, et al. (2011) Evaluation of the Xpert®MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 184(1): 132-140.
14. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, et al. (2011) Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 8(7): e1001061.
15. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, et al. (2011) Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8(7): e1001067.
16. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility and impact of decentralized use of XpertMTB/RIF for the diagnosis of tuberculosis and multidrug resistance-results from a multicenter implementation study. Lancet 377(9776): 1495-1505.
17. WHO (2011) Global Tuberculosis Control 2011. Publication number WHO/HTM/TB/2011.16. World Health Organization, Geneva, Switzerland. Available: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf. Accessed: 2012 Jan 10.
18. Ministerio de Salud (2010) Estrategia Sanitaria Nacional para la Prevención y Control de la Tuberculosis. Informe Operacional Trimestral, Perú. Available: http://www.tbperu.pe/Docs/io/io2010.pdf. Accessed: 2011 Nov 09.
19. Kent PT, Kubica GP, editors (1985) Public health mycobacteriology: a guide for the Level III laboratory. Atlanta: Centers for Disease Control.
20. Hillemann D, Rüsch-Gerdes S, Richter E, (2005) Application of the capilia TB assay for culture confirmation of Mycobacterium tuberculosis complex isolates. Int J Tuberc Lung Dis 9(12): 1409-1411.
21. Helb D, Jones M, Story E, Boehme C, Wallace E, et al. (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48(1): 229-237.
22. Wechsler S (1997) Statistics at Square One. Ninth Edition, revised by M. J. Campbell, T. D. V. Swinscow, BMJ Publ. Group, London, 1996. Available: http://www.bmj.com/about-bmj/resourcesreaders/publications/statistics-square-one. Accessed: 2012 Jun 01.
23. Dean AG, Sullivan KM, Soe MM. (2006) OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. Available: www.OpenEpi.com, updated 2011/23/06. Accessed: 2011 Nov 16.
24. Bossuyt PM, Reitsma JB, Bruns DE Gatsonis CA, Glasziou PP, et al. (2003) Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting of diagnostic accuracy: explanation and elaboration. Clin Chem 49(1): 7-18.
25. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362(8): 697-706.
26. Moure R, Muñoz L, Torres M, Santin M, Martín R, et al. (2011) Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J Clin Microbiol 49(3): 1137-1139.
27. Van Rie A, Mellet K, John MA, Scott L, Page-Shipp L, et al. (2012) False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 16(2): 206-208.
28. WHO (2011) Rapid Implementation of the Xpert MTB/RIF diagnostic test. Publication number WHO/HTM/TB/2011.2. World Health Organization, Geneva, Switzerland. Available: http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf Accessed: 2011 Nov 29.
29. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, et al. (2011) Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. Plos Med 8: e1001120.
30. Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, et al. (2011) Xpert®MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 15(12): 1567-1572.